CSI Market
Sign In | Register

Abbott Laboratories (ABT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ABT Annual Cash Flow →
A period-by-period view of cash flow from Abbott Laboratories to Mar 31 2025 helps clarify how Mar 31 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income1,077.00
Depreciation & amortization381.00
Amortization of Other Assets422.00
Special charges0.00
Restructuring reserve0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-420.00
Purchased in-process R & D0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation317.00
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions0.00
Gains (Losses) on Extinguishment of Debt0.00
Research And Development Asset Acquired Other Than Through Business Combination Written Off Cash Flow Impact-
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities-
Amortization Of Inventory Step Up-
Investing And Financing Gains Losses Net-
Income taxes0.00
Gain (Loss) on Sale of Equity Investments0.00
Increase (Decrease) in Accounts Receivable-42.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Losses/ -gains on investments net0.00
Post-retirement benefits expense0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital-420.00
Other assets & liabilities0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities1,315.00
Investing Activities
Capital Expenditures-399.00
Sale of Capital Items0.00
Payments for (Proceeds from) Investments-161.00
Payments to Acquire Marketable Securities0.00
Proceeds from other investments0.00
Payments To Acquire Businesses Net Of Cash Acquired And Research And Development In Process-19,798.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments for (Proceeds from) Other Investments0.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Proceeds from Sales of Business, Affiliate and Productive Assets0.00
Proceeds from sale of assets0.00
Restricted funds0.00
Payments for (Proceeds from) Other Investing Activities34.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-20,324.00
Financing Activities
Short-term debt Net31.00
Other borrowing transactions0.00
Long-term debt - borrowings19,860.00
Long-term debt - repayments-1,416.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock-64.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net-8,522.00
Business Acquisition Contingent Consideration And Other Consideration Cash Paid-
Payment Of Contingent Consideration-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents8,522.00
Proceeds From Long Term Debt And Debt Maturing In More Than Three Months-
Repayments Of Long Term Debt And Debt Maturing In More Than Three Months-
Dividends paid to minority interests0.00
Dividends paid-1,098.00
Net Cash Flow from Financing Activities17,313.00
Effect of exchange rate on cash flow-23.00
Discontinued operations0.00
Free Cash Flow916.00
Total Cash Flow-1,719.00
4 historic quarters locked

Sign in to unlock the full Abbott Laboratories cash flow history.

Sign In Create Free Account

About Abbott Laboratories Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 28, 2026
  • Source: abt-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-050134

Figures are derived from filed reports and may be restated. Historical data is subject to revision.